135 related articles for article (PubMed ID: 37904277)
1. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap.
Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277
[TBL] [Abstract][Full Text] [Related]
2. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
3. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N
J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.
Yamada Y; Belharazem-Vitacolonnna D; Bohnenberger H; Weiß C; Matsui N; Kriegsmann M; Kriegsmann K; Sinn P; Simon-Keller K; Hamilton G; Graeter T; Preissler G; Ott G; Schölch S; Nakajima N; Yoshizawa A; Haga H; Date H; Thomas RK; Petrini I; Giaccone G; Ströbel P; Marx A
Cell Death Dis; 2022 Nov; 13(11):979. PubMed ID: 36402755
[TBL] [Abstract][Full Text] [Related]
5. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
6. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
[TBL] [Abstract][Full Text] [Related]
7. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
8. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
9. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
10. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y
Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369
[TBL] [Abstract][Full Text] [Related]
11. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
12. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
13. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
15. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract][Full Text] [Related]
16. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
17. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
20. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
